Canvuparatide clinical trials
Also written MBX 2109.
How each study uses canvuparatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the canvuparatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
MBX Biosciences (4)
Studies
Open first, then newest update. How each study uses canvuparatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismRecruitingPhase 3MBX BiosciencesNCT07699471Written as Canvuparatide
- Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismCompletedPhase 2MBX BiosciencesNCT06465108Written as MBX 2109
- Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal FunctionCompletedPhase 1MBX BiosciencesNCT06496217Written as MBX 2109
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsCompletedPhase 1MBX BiosciencesNCT05158335Written as MBX 2109 (Part A)
Codes
What other systems call canvuparatide · ClinicalTrials.gg INT015558
- UNII (FDA) 7YT49ZX2QZCANVUPARATIDEOne source FDA
- NCI Thesaurus C211746CanvuparatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7YT49ZX2QZ | CANVUPARATIDE | One source FDA |
| NCI Thesaurus | C211746 | Canvuparatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.